Skip to site menu Skip to page content
Logo Image
In Brief
Spotlight

Sanofi and Regeneron expand immunology partnership to the tune of $8bn

The agreement will see Sanofi and Regeneron co-develop and co-commercialise four long-lasting antibodies.

Latest news

Varda pockets $251m to back space-based pharma processing mission 

Varda secures this capital as drugmakers tout the potential of manufacturing in microgravity conditions to create differentiated medicines.

EASD 2026: CagriSema weight loss holds at submaximal doses in REDEFINE-1 analysis

Data arrives as drugmakers race to bring successors to popular obesity therapies like semaglutide and tirzepatide to market.

Atossa plans shareholder stake in potential PRV proceeds

Shareholders could be set for a cash reward if the biotech wins a voucher upon approval of (Z)-endoxifen.

EASD 2026: Tirzepatide outperforms semaglutide in real-world type 2 diabetes analysis

Tirzepatide delivers stronger real-world glycaemic and weight-loss outcomes than oral and injectable semaglutide in type 2 diabetes.

BioMarin and Profluent partner on AI-designed enzyme therapies

Under the agreement, Profluent will deploy its proprietary suite of protein language models to generate new potential drug candidates.

Bristol Myers Squibb secures expanded US approval for Camzyos

The regulatory decision was supported by findings from the randomised Phase III SCOUT-HCM trial in 44 adolescent patients.